PubRank

Gertjan Wolbink

Author PubWeight™ 16.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum Mutat 2009 1.62
2 Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011 1.39
3 Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008 1.23
4 Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005 1.22
5 Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012 1.09
6 Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2012 0.97
7 Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol 2012 0.92
8 IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. J Rheumatol 2008 0.92
9 Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. Arthritis Rheumatol 2014 0.90
10 Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford) 2012 0.88
11 Nanomolar to sub-picomolar affinity measurements of antibody-antigen interactions and protein multimerizations: fluorescence-assisted high-performance liquid chromatography. Anal Biochem 2013 0.87
12 Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis 2009 0.87
13 Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskelet Disord 2012 0.84
14 The effects of continuous venovenous hemofiltration on coagulation activation. Crit Care 2006 0.83
15 Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns. Rheumatology (Oxford) 2012 0.79
16 The acute-phase response is not predictive for the development of arthritis in seropositive arthralgia - a prospective cohort study. J Rheumatol 2012 0.79
17 Do C-reactive protein levels help predict onset of rheumatoid arthritis in women? Nat Clin Pract Rheumatol 2007 0.75
18 [TNF inhibitors: the role of drug levels]. Ned Tijdschr Geneeskd 2014 0.75
19 Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients. Rheumatology (Oxford) 2013 0.75